Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma : Systematic Review and Meta-Analysis

Show full item record



Permalink

http://hdl.handle.net/10138/334255

Citation

Järvinen , T , Paajanen , J , Ilonen , I & Räsänen , J 2021 , ' Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma : Systematic Review and Meta-Analysis ' , Cancers , vol. 13 , no. 14 , 3637 . https://doi.org/10.3390/cancers13143637

Title: Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma : Systematic Review and Meta-Analysis
Author: Järvinen, Tommi; Paajanen, Juuso; Ilonen, Ilkka; Räsänen, Jari
Contributor: University of Helsinki, HUS Heart and Lung Center
University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Department of Surgery
University of Helsinki, HUS Heart and Lung Center
Date: 2021-07
Language: eng
Number of pages: 11
Belongs to series: Cancers
ISSN: 2072-6694
URI: http://hdl.handle.net/10138/334255
Abstract: Simple Summary Treatment of malignant mesothelioma with high-temperature chemotherapeutic instillation of the affected pleural space seems to be advantageous, but higher-quality studies are needed. Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Hyperthermic intrathoracic chemoperfusion (HITHOC) is commonly used with surgery in limited disease. However, data on its effect on survival are limited. In this systematic review and meta-analysis, we analyzed a total of 11 observational articles. HITHOC was compared to control arm that did not receive HITHOC in three studies including 762 patients. The pooled analysis of these studies revealed an SMD of 0.24, with 95% CI of 0.06-0.41 favoring the HITHOC group, reaching statistical significance. The survival effect of HITHOC in epithelioid MPM vs. non-epithelioid MPM was analyzed in four studies. Pooled analysis showed an SMD of 0.79 (95% CI = 0.48-1.10) favoring epithelioid MPM. Based on available data, there seems to be a benefit with HITHOC in regards to overall survival in the treatment of all mesothelioma patients. Multicenter randomized controlled trials are needed to validate and standardize this treatment approach.
Subject: malignant pleural mesothelioma
hyperthermic intrathoracic chemoperfusion
EXTRAPLEURAL PNEUMONECTOMY
CYTOREDUCTIVE SURGERY
PHASE-II
INTRAPERITONEAL CHEMOTHERAPY
INTRAPLEURAL IMMUNOCHEMOTHERAPY
PERITONEAL CARCINOMATOSIS
CISPLATIN CHEMOTHERAPY
PLEURECTOMY/DECORTICATION
CANCER
MANAGEMENT
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
cancers_13_03637.pdf 1.203Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record